331 related articles for article (PubMed ID: 35650594)
1. Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies.
Huang J; Li YB; Charlebois C; Nguyen T; Liu Z; Bloemberg D; Zafer A; Baumann E; Sodja C; Leclerc S; Fewell G; Liu Q; Prabhakarpandian B; McComb S; Stanimirovic DB; Jezierski A
Fluids Barriers CNS; 2022 Jun; 19(1):38. PubMed ID: 35650594
[TBL] [Abstract][Full Text] [Related]
2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the alpha
Cobb DA; de Rossi J; Liu L; An E; Lee DW
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
[TBL] [Abstract][Full Text] [Related]
4. Development of a Blood-Brain Barrier Permeability Assay Using Human Induced Pluripotent Stem Cell Derived Brain Endothelial Cells.
Charlebois C; Huang J; Sodja C; Ribecco-Lutkiewicz M; Baumann E; Stanimirovic DB; Jezierski A
Methods Mol Biol; 2022; 2454():397-410. PubMed ID: 33881753
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.
Wang S; Wei W; Yuan Y; Sun B; Yang D; Liu N; Zhao X
J Transl Med; 2023 Jul; 21(1):493. PubMed ID: 37481592
[TBL] [Abstract][Full Text] [Related]
6. Initial contact of glioblastoma cells with existing normal brain endothelial cells strengthen the barrier function via fibroblast growth factor 2 secretion: a new in vitro blood-brain barrier model.
Toyoda K; Tanaka K; Nakagawa S; Thuy DH; Ujifuku K; Kamada K; Hayashi K; Matsuo T; Nagata I; Niwa M
Cell Mol Neurobiol; 2013 May; 33(4):489-501. PubMed ID: 23385422
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
8. Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma.
Abbott RC; Iliopoulos M; Watson KA; Arcucci V; Go M; Hughes-Parry HE; Smith P; Call MJ; Cross RS; Jenkins MR
Clin Transl Immunology; 2023; 12(3):e1440. PubMed ID: 36890859
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight.
Land CA; Musich PR; Haydar D; Krenciute G; Xie Q
J Transl Med; 2020 Nov; 18(1):428. PubMed ID: 33176788
[TBL] [Abstract][Full Text] [Related]
10. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
12. Mouse embryonic stem cell-derived blood-brain barrier model: applicability to studying antibody triggered receptor mediated transcytosis.
Jezierski A; Huang J; Haqqani AS; Haukenfrers J; Liu Z; Baumann E; Sodja C; Charlebois C; Delaney CE; Star AT; Liu Q; Stanimirovic DB
Fluids Barriers CNS; 2023 May; 20(1):36. PubMed ID: 37237379
[TBL] [Abstract][Full Text] [Related]
13. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
14. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
[TBL] [Abstract][Full Text] [Related]
15. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
Johnson LA; Scholler J; Ohkuri T; Kosaka A; Patel PR; McGettigan SE; Nace AK; Dentchev T; Thekkat P; Loew A; Boesteanu AC; Cogdill AP; Chen T; Fraietta JA; Kloss CC; Posey AD; Engels B; Singh R; Ezell T; Idamakanti N; Ramones MH; Li N; Zhou L; Plesa G; Seykora JT; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2015 Feb; 7(275):275ra22. PubMed ID: 25696001
[TBL] [Abstract][Full Text] [Related]
16. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
17. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
19. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
Maggs L; Cattaneo G; Dal AE; Moghaddam AS; Ferrone S
Front Neurosci; 2021; 15():662064. PubMed ID: 34113233
[TBL] [Abstract][Full Text] [Related]
20. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.
Del Baldo G; Del Bufalo F; Pinacchio C; Carai A; Quintarelli C; De Angelis B; Merli P; Cacchione A; Locatelli F; Mastronuzzi A
Front Immunol; 2023; 14():1142597. PubMed ID: 37025994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]